FDA, CDC and EMA recommend a pause in chikungunya vaccine use in people 60 or 65 years of age or older while postmarketing safety reports are being investigated.
Reduced incidence may result from single people's greater social interactions and community involvement, authors say. Or is it that it is not as readily detected or reported?